ReviewFrontiers in immunology2026
From integrative diagnostics to personalised management: a framework combining molecular and spatial immune profiling in NSMP endometrial carcinoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma (EC) of the No Specific Molecular Profile (NSMP) subtype, the largest molecular category, exhibits marked clinical heterogeneity that challenges morphology-based risk assessment. Two complementary biomarker categories have demonstrated independent prognostic value: protein-level markers (L1CAM, oestrogen receptor [ER], and progesterone receptor [PR]) detectable by routine immunohistochemistry and spatially resolved cancer-immune phenotypes (SCIs) that characterize the tumour immune microenvironment. This review synthesises evidence for both, highlighting that they are often considered in isolation. We argue that their systematic integration is essential for a more precise diagnostic framework. We articulate the biological rationale and propose a testable "dual-risk" hypothesis, whereby combined molecular and immune profiling could identify extreme-risk populations. Realising this integrative model requires overcoming standardisation hurdles, but it represents a critical step towards predictive, functionally informed stratification to guide personalised adjuvant therapy decisions, including intensification and de-escalation. We emphasise that this framework remains a testable hypothesis requiring prospective validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.